Elliot S. Barnathan

机构：Johnson & Johnson (United States), Janssen (Belgium), Janssen (United States), JK Research (United States) · ORCID：0000-0001-7744-1486

发表论文 163 篇 · 总被引 12601 次 · h-index 52

代表论文

• Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study (2021 · American Heart Journal · 被引 44)
• Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients (2021 · Journal of the American Heart Association · 被引 43)
• Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial (2023 · Circulation · 被引 30)
• Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS) (2025 · American Heart Journal · 被引 16)
• Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA (2021 · Drug Safety · 被引 16)
• Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial (2024 · Frontiers in Cardiovascular Medicine · 被引 14)